Why did NTRA's Q3 earnings exceed forecasts?

Natera's Q3 earnings exceeded forecasts due to significant growth in test volumes across its three main business segments, increase in average selling prices and one-time financial adjustments. The company's flagship product, Signatera, experienced substantial growth, with over half a million tests conducted in fiscal year 2024, surpassing expectations. Natera's financial performance was further boosted by potential improvements in average selling prices due to better Medicare Advantage coverage and anticipated modest improvements in Signatera’s average selling prices.